1192815-01-2

Usage

Uses

Used in Organic Synthesis:
5-Bromoisoquinolin-3-amine is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure and reactivity make it a versatile component in the development of new compounds with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Bromoisoquinolin-3-amine is used as a key intermediate in the synthesis of pharmaceutical drugs. Its potential applications in the development of new therapeutic agents make it of interest to medicinal chemists and pharmaceutical companies.
Used in the Development of New Therapeutic Agents:
5-Bromoisoquinolin-3-amine has potential applications in the development of new therapeutic agents due to its unique structure and reactivity. Its ability to modulate the physicochemical and pharmacological properties of molecules makes it a promising candidate for the creation of innovative drugs with improved efficacy and safety profiles.

Upstream product

• 1192815-00-1 N-(3-bromo-benzyl)-2,2-diethoxy-acetamidine 
• 39959-54-1 3-bromobenzylamine hydrochloride 

Relevant academic research and scientific papers

Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents

Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

Isoquinolin-3-Ylurea Derivatives

The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R1 represents (C1-C3)alkyl, (C1-C3)haloalkyl or cyclopropyl, R4 represents H and the substituents R2 and R3 and R5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.

ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES

The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R1 represents (C1-C3)alkyl, (C1-C3)haloalkyl or cyclopropyl, R4 represents H and the substituents R2 and R3 and R5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections.